New bladder cancer drug shows promise in early trial
NCT ID NCT05375903
First seen Jan 19, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This early-stage study tested a new drug called UGN-301 (zalifrelimab) in 51 people with recurrent non-muscle invasive bladder cancer. The drug was given directly into the bladder to see if it is safe and to find the best dose. The goal is to control the cancer and prevent it from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arkansas Urology
Little Rock, Arkansas, 72211, United States
-
Clinical Research Solutions
Middleburg Heights, Ohio, 44130, United States
-
Florida Urology Partners, LLC
Tampa, Florida, 33615, United States
-
Hospital Clinic de Barcelona Instituto Clinic de Nefrologia y Urologia (ICNU)
Barcelona, 08036, Spain
-
I.R.C.C.S. Ospedale San Raffaele
Milan, Italy
-
Istituto Oncologico Veneto
Padova, Italy
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Manhattan Medical Research
New York, New York, 10016, United States
-
NEXT Oncology IOB- Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
NEXT Oncology- Hospital Quironsalud Mardrid
Madrid, 28223, Spain
-
National Tumor Institute Fondazione G. Pascale
Naples, Italy
-
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
-
UCLA - University of California
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.